EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Silexan in anxiety, depression, and related disorders: pharmacological background and clinical data

Siegfried Kasper, Anne Eckert

European Archives of Psychiatry and Clinical Neuroscience · 2025

DOI: 10.1007/s00406-024-01923-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Archives of Psychiatry and Clinical Neuroscience, 2025. Verfasst von Siegfried Kasper und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Neuroscience, Center of Brain Research, Medical University of Vienna, Spitalgasse 4, Vienna, A-1090, Austria. siegfried.kaspe…. Hauptthemen laut MEDLINE: Anxiety Disorders, Anti-Anxiety Agents, Plant Oils, Antidepressive Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We present a narrative review of clinical trials investigating the anxiolytic and antidepressant effects of silexan, an active substance derived from lavender oil and summarize nonclinical findings from pharmacological studies supporting its therapeutic use. Six studies investigated the efficacy of the lavender oil in patients with subthreshold and generalized anxiety disorders as well as in mixed anxiety and depressive disorder (MADD). Furthermore, we present data indicating that silexan may influence sleep quality as well as anxiety or depressive disorders in individuals with post-COVID-19. Silexan taken orally at a daily dose of 80 mg for 10 weeks was significantly superior to placebo in reducing psychic and somatic symptoms of anxiety and was as effective as 0.5 mg/d lorazepam and 20 mg/d paroxetine. In patients with mild or moderate major depression, silexan was superior to placebo and comparably effective to 50 mg/d sertraline. Significant antidepressant effects were also observed in MADD and depression co-morbid with anxiety. The herbal product had a beneficial effect on activities of daily living and health-related quality of life. Adverse events associated with silexan in clinical trials were limited to eructation and mild, transient gastrointestinal complaints. The herbal product was not associated with drug interactions, sedation, sleep disturbance, dependence and abuse potential, sexual dysfunction, weight gain or withdrawal symptoms. Silexan was therefore safe and effective in subthreshold and syndromal anxiety disorders and in major depression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anxiety DisordersAnti-Anxiety AgentsPlant OilsAntidepressive AgentsCOVID-19Oils, VolatileDepressive DisorderHumansLavandula

Stichwörter der Autor:innen

Anxiety disorderDepressionLavender oilPharmacologyReviewSilexanpost-COVID-19

Substanzen

Anti-Anxiety Agentslavender oilPlant OilsAntidepressive AgentsOils, Volatile

Autor:innen und Institutionen

  • Department of Molecular Neuroscience, Center of Brain Research, Medical University of Vienna, Spitalgasse 4, Vienna, A-1090, Austria. siegfried.kasper@meduniwien.ac.at.
  • Neurobiology Laboratory for Brain Aging and Mental Health, Psychiatric University Clinics Basel, Basel, Switzerland.
  • Research Platform Molecular and Cognitive Neurosciences, University of Basel, Basel, Switzerland.

Förderung

  • Medical University of Vienna

Zitieren

APA

Kasper, S., & Eckert, A. (2025). Silexan in anxiety, depression, and related disorders: pharmacological background and clinical data. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-024-01923-8

Vancouver

Kasper S, Eckert A. Silexan in anxiety, depression, and related disorders: pharmacological background and clinical data. European Archives of Psychiatry and Clinical Neuroscience. 2025. doi:10.1007/s00406-024-01923-8

BibTeX
@article{Kasper2025,
  author = {Kasper, Siegfried and Eckert, Anne},
  title = {Silexan in anxiety, depression, and related disorders: pharmacological background and clinical data},
  journal = {European Archives of Psychiatry and Clinical Neuroscience},
  year = {2025},
  doi = {10.1007/s00406-024-01923-8}
}
Kostenlos starten →